A Delphi consensus approach across 11 domains provides a framework for risk assessment, screening, and follow-up specific to pediatric cancer therapeutics.
This Delphi consensus provides a specific approach for risk assessment, screening, and follow-up in pediatric cardio-oncology, addressing a gap in current international guidelines.
Cardio-oncology is a new multidisciplinary area of expertise that seeks to pre-emptively and proactively address cardiac complications that emerge during and following cancer therapy. Modern therapies including molecular targeted therapy and immunotherapy have broadened the agents that can cause cardiac sequelae, often with complications arising within days to weeks of therapy. Several international guidelines have been developed for the acute monitoring of cardio-oncology side effects. However, none are specific to pediatrics. We have addressed this gap in the literature by undertaking a rigorous Delphi consensus approach across 11 domains of cardio-oncology care using an Australian and New Zealand expert group. The expert group consisted of pediatric and adult cardiologists and pediatric oncologists. This Delphi consensus provides an approach to perform risk and baseline assessment, screening, and follow-up, specific to the cancer therapeutic. This review is a useful tool for clinicians involved in the cardio-oncology care of pediatric oncology patients.
Toro et al. (Thu,) conducted a review in Cardio-oncology complications in pediatric oncology patients. Delphi consensus recommendations for cardio-oncology care was evaluated. A Delphi consensus approach across 11 domains provides a framework for risk assessment, screening, and follow-up specific to pediatric cancer therapeutics.